Mars network for enabling low-cost missions by Hastrup, R.C., Bell, D.J., Cesarone, R.J., Edwards, C.D., Ely, T.A., Guinn, J.R., Rosell, S.N., Srinivasan, J.M., Townes, S.A.

Get full text

Strategies for telecommunications and navigation in support of Mars exploration by Edwards, C.D., Adams, J.T., Bell, D.J., Cesarone, R., DePaula, R., Durning, J.F., Ely, T.A., Leung, R.Y., McGraw, C.A., Rosell, S.N.

Get full text

1330 Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial by Rosell, R., Gettinger, S.N., Bazhenova, L.A., Langer, C.J., Salgia, R., Shaw, A.T., Narasimhan, N.I., Dorer, D.J., Kerstein, D., Camidge, D.R.

Get full text

3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study by Camidge, D.R, Bazhenova, L.A, Salgia, R, Langer, C.J, Gold, K, Rosell, R, Shaw, A.T, Weiss, G.J, Dorer, D.J, Rivera, V.M, Conlan, M.G, Kerstein, D, Gettinger, S.N

Get full text

56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results by Gettinger, S.N, Bazhenova, L.A, Salgia, R, Langer, C.J, Gold, K, Rosell, R, Shaw, A.T, Weiss, G.J, Dorer, D.J, Rivera, V.M, Kerstein, D, Camidge, D.R

Get full text

81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases by Gettinger, S.N, Bazhenova, L, Salgia, R, Langer, C.J, Gold, K.A, Rosell, R, Shaw, A.T, Weiss, G.J, Narasimhan, N.I, Dorer, D.J, Rivera, V.M, Clackson, T, Haluska, F.G, Camidge, D.R

Get full text